ストックスクリーナーアプリを入手
35.22
4.36%
1.47
前日終値:
$33.75
開ける：
$34.32
24時間の取引高:
969.74K
Relative Volume:
1.22
時価総額：
$2.02B
収益：
$32.87M
当期純損益:
$674.31M
株価収益率:
3.1004
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
+6.02%
1か月 パフォーマンス:
+5.99%
6か月 パフォーマンス:
-25.22%
1年 パフォーマンス:
+31.42%
1日の値動き範囲:
$33.75
$35.30
1週間の範囲:
$33.18
$35.30
52週間の値動き範囲:
$26.66
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
35.22 | 2.02B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 開始されました | Piper Sandler | Overweight |
| 2022-11-17 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-02-15 | 繰り返されました | Needham | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-08-10 | 繰り返されました | Needham | Buy |
| 2017-08-08 | 繰り返されました | SunTrust | Buy |
| 2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | ダウングレード | Janney | Buy → Neutral |
| 2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 開始されました | Needham | Buy |
| 2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January - MarketBeat
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - The Manila Times
Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem - Simply Wall St
Rare Disease Leader Agios Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan
Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to "Sell" - MarketBeat
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues - MSN
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates - MSN
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank - Yahoo Finance
Agios Pharmaceuticals announces board resignation - MSN
Long Term Trading Analysis for (AGIO) - Stock Traders Daily
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade) - Seeking Alpha
Positive Phase III ACTIVATE-Kids study of Agios’ mitapivat - The Pharma Letter
Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlight - GuruFocus.com
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress - TipRanks
Agios Pharmaceuticals targets multi-billion-dollar growth with Pyrukynd expansion in 2025 - MSN
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years - Benzinga
Agios Pharmaceuticals, Inc. Announces Resignation of David P. Schenkein, M.D from Board of Directors and Member of the Science and Technology Committee, Effective February 28, 2025 - Marketscreener.com
Research Analysts Offer Predictions for AGIO FY2024 Earnings - MarketBeat
Agios Pharmaceuticals Inc. (AGIO) reports earnings - Quartz
Agios Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Agios Pharmaceuticals announces board resignation By Investing.com - Investing.com Nigeria
Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises - Investing.com UK
Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint - The Manila Times
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Agios Pharma Board Member Announces Resignation - TipRanks
Clinical Trial Breakthrough: Agios' Blood Disorder Drug Outperforms Placebo in Rare Pediatric Disease - StockTitan
Rep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock - Defense World
Agios Pharmaceuticals Q4 2024 Earnings Preview - MSN
Agios Pharmaceuticals price target lowered to $54 from $55 at BofA - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now - Insider Monkey
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
Beta Thalassemia Treatment Market Size Report 2032 | Novartis, - openPR
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results - MSN
Biliary Tract Cancer Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Onco - Barchart
Q4 Earnings Alert: Agios Pharmaceuticals Sets Critical Financial Update for Rare Disease Pipeline - StockTitan
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 - The Manila Times
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
Agios Pharmaceuticals Inc (AGIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Washburn Theodore James Jr. | Principal Accounting Officer |
Feb 05 '25 |
Sale |
34.39 |
2,272 |
78,134 |
5,437 |
| Milanova Tsveta | Chief Commercial Officer |
Jan 03 '25 |
Option Exercise |
0.00 |
8,476 |
0 |
21,710 |
| Milanova Tsveta | Chief Commercial Officer |
Jan 06 '25 |
Sale |
32.18 |
2,804 |
90,233 |
18,906 |
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):